title: Natural killer-like T-cell lymphoma of the parotid in a patient infected with human immunodeficiency virus.
abstract: A 42-year-old man with acquired immunodeficiency syndrome developed a mass of the right parotid gland and multiple hepatic masses. Hematoxylin-eosin-stained sections of the parotid lesion showed a diffuse infiltrate of large mononuclear cells with vesicular nuclei and prominent nucleoli, consistent with a non-Hodgkin lymphoma. Immunohistochemical stains demonstrated expression of the T-cell markers CD3 and UCHL-1, as well as latent membrane protein 1 and T-cell intracellular antigen 1. Flow cytometry showed surface expression of CD2, CD3, CD7 (dim), CD8, and CD56. CD5 was not expressed. Molecular evaluation by polymerase chain reaction demonstrated monoclonal rearrangement of the T-cell receptor gamma gene. Epstein-Barr virus early RNA and human immunodeficiency virus RNA were demonstrated by in situ hybridization. To our knowledge, this is the first reported case of T-cell lymphoma of the parotid in a patient infected with human immunodeficiency virus. After 2 separate chemotherapy regimens, the patient achieved clinical remission for 1(1/2) years; he then developed progressive pulmonary lesions and died.
authors.affiliation: Department of Pathology, University of Florida College of Medicine, Gainesville, USA. cornf1@dca.net
authors.forename: Dennis B
authors.initials: DB
authors.lastname: Cornfield
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Papiez
authors.forename: James T
authors.initials: JT
authors.lastname: Lynch
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Rimsza
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D003520:Cyclophosphamide / Q000008:administration & dosage; D004273:DNA, Neoplasm / Q000032:analysis; D004317:Doxorubicin / Q000008:administration & dosage; D017809:Fatal Outcome; D005434:Flow Cytometry; D015334:Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / Q000235:genetics; D006678:HIV / Q000235:genetics / Q000302:isolation & purification*; D004854:Herpesvirus 4, Human / Q000302:isolation & purification / Q000502:physiology; D006801:Humans; D007694:Killer Cells, Natural / Q000473:pathology*; D017493:Leukocyte Common Antigens / Q000032:analysis; D016483:Lymphoma, AIDS-Related / Q000276:immunology / Q000473:pathology* / Q000821:virology; D016399:Lymphoma, T-Cell / Q000276:immunology / Q000473:pathology* / Q000821:virology; D008297:Male; D010307:Parotid Neoplasms / Q000276:immunology / Q000473:pathology* / Q000821:virology; D016133:Polymerase Chain Reaction; D011241:Prednisone / Q000008:administration & dosage; D012367:RNA, Viral / Q000032:analysis; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D012367:RNA, Viral; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D017493:Leukocyte Common Antigens; D011241:Prednisone